Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ABCZF OTCMKTS:ATTBF OTCMKTS:FFNTF OTCMKTS:MMEDF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCZFAbcamC$22.25C$22.25C$5.00▼C$23.80N/AN/A2,659 shsN/AATTBFAbattis Bioceuticals$0.00$0.00▼$0.00N/AN/A11,650 shs945 shsFFNTF4Front Ventures$0.00$0.00▼$0.07N/AN/A1.28 million shsN/AMMEDFMind Medicine (MindMed)$44.79+6.3%$23.67$0.29▼$5.07N/AN/A3.38 million shs8.29 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCZFAbcam0.00%0.00%0.00%0.00%0.00%ATTBFAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%FFNTF4Front Ventures0.00%0.00%0.00%0.00%-50.00%MMEDFMind Medicine (MindMed)+16.45%+72.45%+87.24%+136.82%+489.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCZFAbcamC$22.25C$22.25C$5.00▼C$23.80N/AN/A2,659 shsN/AATTBFAbattis Bioceuticals$0.00$0.00▼$0.00N/AN/A11,650 shs945 shsFFNTF4Front Ventures$0.00$0.00▼$0.07N/AN/A1.28 million shsN/AMMEDFMind Medicine (MindMed)$44.79+6.3%$23.67$0.29▼$5.07N/AN/A3.38 million shs8.29 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCZFAbcam0.00%0.00%0.00%0.00%0.00%ATTBFAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%FFNTF4Front Ventures0.00%0.00%0.00%0.00%-50.00%MMEDFMind Medicine (MindMed)+16.45%+72.45%+87.24%+136.82%+489.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCZFAbcam 0.00N/AN/AN/AATTBFAbattis Bioceuticals 0.00N/AN/AN/AFFNTF4Front Ventures 0.00N/AN/AN/AMMEDFMind Medicine (MindMed) 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCZFAbcamN/AN/AN/AN/AN/AN/AATTBFAbattis BioceuticalsN/AN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/AN/AMMEDFMind Medicine (MindMed)N/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCZFAbcamN/AC$0.17130.73N/AN/AN/AN/AN/AN/AATTBFAbattis BioceuticalsN/A-$0.16N/AN/AN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/AN/AN/AN/AN/AMMEDFMind Medicine (MindMed)N/AN/AN/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABCZFAbcamC$0.070.32%N/A42.48%N/AATTBFAbattis BioceuticalsN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/AMMEDFMind Medicine (MindMed)N/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCZFAbcam43.58%ATTBFAbattis Bioceuticals32.45%FFNTF4Front VenturesN/AMMEDFMind Medicine (MindMed)N/AInsider OwnershipCompanyInsider OwnershipABCZFAbcamN/AATTBFAbattis BioceuticalsN/AFFNTF4Front VenturesN/AMMEDFMind Medicine (MindMed)N/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCZFAbcam1,750N/AN/ANot OptionableATTBFAbattis BioceuticalsN/AN/AN/ANot OptionableFFNTF4Front Ventures460N/AN/ANot OptionableMMEDFMind Medicine (MindMed)40N/AN/ANot OptionableMMEDF, FFNTF, ATTBF, and ABCZF HeadlinesRecent News About These CompaniesMind Medicine (MNMD) price target increased by 11.49% to 29.15January 14, 2026 | msn.comWhy Mind Medicine (MindMed) Inc.’s (MNMD) Stock Is Down 5.21%December 24, 2025 | aaii.comAJones Trading initiates coverage of Mind Medicine (MNMD) with buy recommendationDecember 24, 2025 | msn.comMind Medicine initiated with a Buy at JonesResearchDecember 23, 2025 | msn.comCanaccord Genuity Maintains Mind Medicine (MNMD) Buy RecommendationNovember 8, 2025 | msn.comMind Medicine initiated with a Buy at NeedhamOctober 13, 2025 | msn.comMind Medicine participates in a conference call with Cantor FitzgeraldSeptember 22, 2025 | msn.comPsychedelic: Exclusive talk with biopharma company MindMedSeptember 18, 2025 | msn.comMind Medicine announces publication of results from MM120 Phase 2b studySeptember 4, 2025 | msn.comMind Medicine upgraded at Oppenheimer on lead assetAugust 5, 2025 | msn.comMindMed outlines 2026 Phase III trial readouts and advances MM120 commercialization with new CFOJuly 31, 2025 | msn.comMindMed to Participate in June Investor ConferencesMay 28, 2025 | financialpost.comFMindMed to Participate in June Investor ConferencesMay 28, 2025 | financialpost.comFMind Medicine (MindMed) Inc. (MNMD): Analysts See 285% Upside PotentialMay 21, 2025 | insidermonkey.comWhy Mind Medicine Stock Vaulted More Than 8% Higher TodayMay 20, 2025 | fool.comWas Jim Cramer Right About Mind Medicine (MNMD) Stock?May 16, 2025 | insidermonkey.comMind Medicine (MindMed) Inc. (MMED.NE)May 8, 2025 | ca.finance.yahoo.comMind Medicine: Strong Data, But Psychedelic Stigma Still Clouds Investor ConfidenceApril 23, 2025 | seekingalpha.comMind Medicine: Initiating Hold Rating Due To Regulatory ChallengesApril 20, 2025 | seekingalpha.comPsychedelic: MindMed announces dosing in Phase 3 Emerge studyApril 17, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMMEDF, FFNTF, ATTBF, and ABCZF Company DescriptionsAbcam OTCMKTS:ABCZFC$22.25 0.00 (0.00%) As of 06/25/2026Abcam Limited, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. Abcam Limited was formerly known as Abcam plc and changed its name to Abcam Limited in December 2023. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom. As of December 6, 2023, Abcam Limited operates as a subsidiary of Danaher Corporation.Abattis Bioceuticals OTCMKTS:ATTBFAbattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.4Front Ventures OTCMKTS:FFNTF4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. The company operates through THC Cannabis and CBD Wellness segments. THC Cannabis segment engages in the cultivation, production, manufacturing, and distribution of THC cannabis products to owned dispensaries and third party retailers; and provision of ancillary services. This segment sells equipment, supplies, and intellectual property to cannabis producers; and leases real estate properties. The CBD Wellness segment sells non-THC hemp derived products. In addition, it operates dispensaries in the Massachusetts, Illinois, and Michigan primarily under the MISSION brand name. 4Front Ventures Corp. was founded in 2011 and is based in Phoenix, Arizona.Mind Medicine (MindMed) OTCMKTS:MMEDF$44.79 +2.66 (+6.31%) As of 06/25/2026Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab's NASA Win Tests Key Support After Sharp Pullback BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Xcel Energy Stock Offers Stability as Electricity Demand Builds Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
